Thu, Jul 24, 2014, 9:16 AM EDT - U.S. Markets open in 14 mins.


% | $
Click the to save as a favorite.

Cardiome Pharma Corp. Message Board

  • frankfurter60 frankfurter60 May 13, 2013 9:29 AM Flag

    Q1 Summary just released

    We recorded a net income of $18.4 million ($1.47 per common share) for the three months ended March 31, 2013 (Q1-2013), compared to a net loss of $7.0 million ($0.57 per common share) for the three months ended March 31, 2012 (Q1-2012). The net income for Q1-2013 was primarily due to the recognition of a $20.8 million gain on the settlement of debt owed to Merck. The net loss for Q1-2012 was due to restructuring charges, clinical development efforts, pre-clinical research projects, as well as other operating costs.

    Total revenue for Q1-2013 was $0.1 million as compared to $0.4 million in Q1-2012.

    Research and development expenditures were $0.4 million for Q1-2013 compared to $2.9 million for Q1-2012. Selling, general and administration expenditures for Q1-2013 were $2.2 million compared to $2.6 million for Q1-2012. Effective Q1-2013, selling, general and administration expenditures include costs incurred to support the commercialization of BRINAVESSTM. We did not incur any interest expense during Q1-2013 as a result of the settlement of debt owed to Merck. Interest expense for Q1-2012 was $1.1 million.

    Stock-based compensation, a non-cash item included in operating expenses, remained consistent at $0.1 million for Q1-2013 and Q1-2012.

    Liquidity and Outstanding Share Capital

    At March 31, 2013, the Company had cash and cash equivalents of $25.7 million. As of May 6, 2013, the Company had 12,470,335 common shares issued and outstanding and 1,321,242 common shares issuable upon the exercise of outstanding stock options at a weighted-average exercise price of CAD $10.27 per share.

6.86Jul 23 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
General Motors Company
NYSEWed, Jul 23, 2014 4:01 PM EDT
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT